Leave R&D tax credits alone, warns Medicines Australia
This article was originally published in Scrip
Executive Summary
Winding back Australia's R&D tax credit system could cause some companies to stop bringing R&D investment dollars to Australia, warned Dr Brendan Shaw, chief executive of Medicines Australia, in a statement today. His comments come in response to Australian media reports that the government may change the tax credit system in the forthcoming federal budget.